NAMS
NewAmsterdam Pharma Company N.V.
22.80$
-1.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 1.1% | 0.8% | – | 0.4% | – | 0.2% | 18.4% | 184.4% | 16.4% | – | – | |
| 100.0% | 100.0% | 98.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -84.4% | 83.6% | 100.0% | 92.1% | |
| 1,474.7% | 5,142.2% | 3,028.6% | 1,684.0% | 122.6% | 273.2% | 1,502.7% | 143.7% | 8,899.7% | 120,606.3% | 1,233.9% | 1,126.0% | 2,088.9% | |
| 271.5% | 856.7% | 677.0% | 516.7% | 47.2% | 277.6% | 911.8% | 142.4% | 7,046.0% | 85,496.9% | 771.4% | 726.6% | 1,435.5% | |
| 1,785.1% | 6,460.4% | 4,021.2% | 2,406.9% | 185.9% | 438.5% | 2,414.5% | 286.1% | 15,945.7% | 206,103.1% | 2,005.3% | 1,852.6% | 3,524.4% | |
| -1,685.1% | -6,360.4% | -3,922.3% | -2,306.9% | -85.9% | -338.5% | -2,314.5% | -186.1% | -15,845.7% | -206,187.5% | -1,921.7% | -1,752.6% | -3,432.2% | |
| 32.7% | 215.6% | 47.6% | 37.4% | 3.9% | 25.1% | – | – | – | – | – | – | – | |
| -1,602.6% | -6,160.4% | -6,692.9% | -1,711.6% | -57.2% | -721.7% | -1,327.3% | -90.7% | -20,691.1% | -234,134.4% | -1,593.5% | -1,732.9% | -3,644.2% | |
| 0.4% | 3.4% | -221.1% | -543.7% | 0.0% | – | – | – | – | – | – | – | – | |
| -1,602.6% | -6,163.8% | -6,692.9% | -1,711.6% | -57.2% | -721.7% | -1,327.3% | -90.7% | -20,691.1% | -234,134.4% | -1,593.5% | -1,732.9% | -3,644.2% | |
| -1,569.4% | -6,349.6% | -3,921.2% | -2,254.5% | -81.9% | -874.5% | -1,325.6% | -90.5% | -20,672.7% | -233,950.0% | -1,591.4% | -1,612.9% | -3,579.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.